Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

October 16, 2023 / 2023 Power 25 Health Care

2023 Power 25 Health Care: Krishnan Nandabalan

Krishnan Nandabalan is president and CEO of Guilford-based InveniAI, which uses artificial intelligence to discover and develop new drugs.

The company is pursuing potential treatments for ailments such as irritable bowel syndrome, inflammatory bowel disease and more.

For more than a decade, Nandabalan has applied AI, big data analytics and machine learning in the healthcare field.

Earlier this year, InveniAI launched a new tool that incorporates GPT-4 by OpenAI, the artificial intelligence behind the ChatGPT chatbot. The tool, called ChatAlphaMeld, is designed to give answers and insights for drug and target discovery.

InveniAI’s AlphaMeld highlights associations between genes, targets, pathways, biomarkers, drugs, diseases and symptoms. Its database includes information on 49,000 drugs, 20,000 genes, 30,000 disease and symptoms, 73,000 expression datasets, and 1,400 cell types, for example.

Nandabalan led the 2017 spinout of BioXcel Therapeutics and InveniAI from parent company BioXcel LLC. While InveniAI is focused on artificial intelligence applications for drug discovery, its sister company, BioXcel Therapeutics, is focused on neuroscience.

BioXcel’s clinical stage subsidiary, OnkosXcel Therapeutics, is developing medicines in immuno-oncology.

Nandabalan is a serial entrepreneur with over two decades of experience in the pharmaceutical and biotechnology industries. Nandabalan is also founder, chairman, president and CEO of Guilford-based Invea Therapeutics, which is focused on using AI to find treatments for inflammation.

Previously, Nandabalan had executive positions at Genaissance Pharmaceuticals and CuraGen Corp.

Sign up for Enews


Order a PDF